Skip to main content
. 2020 Mar 3;7(2):ENEURO.0474-19.2020. doi: 10.1523/ENEURO.0474-19.2020

Figure 1.

Figure 1.

Reduction of MAP2-negative areas and infarct volume in the subacute phase is attenuated in Pdgfrb+/– mice. A, MAP2 staining on days 1, 7, 14, and 28 after pMCAO in wild-type and Pdgfrb+/– mice (scale bar, 500 μm). B, Quantification of MAP2-negative areas on days 1, 7, 14, and 28 after pMCAO (n = 6, each group). C, Quantification of infarct volume on days 1, 7, 14, and 28 after pMCAO (n = 6, each group). D, Quantification of tissue atrophy on day 28 after pMCAO (n = 6, each group). Data are shown as the mean ± SEM. B, D, *p < 0.05 and **p < 0.01, unpaired t test. C, *p < 0.05, one-way ANOVA followed by Bonferroni’s post hoc test. n.s.: not significant.